GRAY MICHAEL sold $5K of UPB

GRAY MICHAEL (CFO and COO) sold 853 shares of Upstream Bio, Inc. (UPB) at $6.10 on 2026-06-16.

Original reporting
SEC EDGAR · GRAY MICHAEL
Published Jun 17, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$UPB
Neutral
medium confidence
Mentioned
$UPB
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UPBNeutralLow
01

Why it matters

The newest fact is the specific open-market sale by the CFO/COO, including date, share count, price, and post-transaction holdings.

02

Market read

Traders may monitor for clustering of insider activity, but this single small sale is unlikely to move the stock materially by itself.

03

What to watch

Insider sales can be driven by taxes, diversification, or personal liquidity; without follow-on buys/sales or larger transactions, the trading signal is weak.

Relevance 3/10Novelty 8/10Timing: today’s SEC Form 4 filing (filed 2026-06-17)

Background

This is an SEC Form 4 insider transaction disclosure for Upstream Bio, Inc. (UPB).

Company-level read

Ticker impact

$UPBNeutralMedium confidence
Context

Upstream Bio CFO/COO Michael Gray sold 853 shares in an open-market transaction on 2026-06-16 at $6.10/share, per Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is primary-source and time-stamped, but the transaction value (~$5.2k) is modest and does not indicate a company-level catalyst.

Market effects

No clear sector read-through from a small, single-insider sale.

None indicated.

None indicated.

Counterpoint

The absence of a 10b5-1 plan could be interpreted as discretionary liquidity rather than bearish conviction, especially given the small size.

Key entities

  • Upstream Bio, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Michael Gray

    CFO and COO who sold 853 shares on 2026-06-16.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UPBMed

Upstream Bio Reports Q3 2026 Results, Plans Phase 3 Trials for 2027

Upstream Bio reported a Q3 2026 net loss of $41.2M, up from $33.7M a year earlier, with collaboration revenue of $395K. The company has $207.4M in cash, expecting to fund operations through 2027. Upstream Bio plans to start Phase 3 trials for verekitug in severe asthma and CRSwNP in Q1 2027, with additional trials in COPD and severe asthma expected to report data in 2027.

$UPBMed

Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress

Upstream Bio, Inc. (UPB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress – Company plans to initiate Phase 3 trials in both severe asthma and CRSwNP in the first quarter of 2027 – – Prioritizing Phase 3 development strategy designed to deliver best-in-class eff

$UPBMed

Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress

Upstream Bio, Inc. (UPB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress – Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-o